Chronic Kidney Disease (Chronic Renal Failure) (Genitourinary Disorders) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease – Drugs In Development, 2021, provides an overview of the Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 19, 17, 4, 46, 21 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 5 molecules, respectively.

Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Genito Urinary System And Sex Hormones).

– The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Acacia Pharma Ltd

Algernon Pharmaceuticals Inc

Algomedix Inc

Allena Pharmaceuticals Inc

Angion Biomedica Corp

Angiotensin Therapeutics Inc

Annji Pharmaceutical Co Ltd

Arch Biopartners Inc

Aria Pharmaceuticals Inc

Aronora Inc

Ashvattha Therapeutics LLC

AstraZeneca Plc

Bayer AG

BerGenBio ASA

BioAegis Therapeutics Inc

BioMarin Pharmaceutical Inc

Boehringer Ingelheim International GmbH

Boryung Pharmaceutical Co Ltd

Cadila Healthcare Ltd

Caladrius Biosciences Inc

Cellmid Ltd

Chinook Therapeutics Inc

Chong Kun Dang Holdings Corp

Cinkate Corp

Daiichi Sankyo Co Ltd

DiaMedica Therapeutics Inc

Dimerix Ltd

Dizal (Jiangsu) Pharmaceutical Co Ltd

DJS Antibodies Ltd

DURECT Corp

Evotec SE

Future Medicine Co Ltd

G3 Pharmaceuticals Inc

GNI Group Ltd

Goldilocks Therapeutics Inc

Gubra ApS

Helixmith Co Ltd

Icagen Inc

Immunitor Inc

Indalo Therapeutics Inc (Inactive)

INVENT Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

KBP Biosciences Holdings Ltd

Kibow Biotech Inc

KidneyCure Ltd

Klotho Therapeutics Inc

Lignamed LLC

Liminal BioSciences Inc

Lung Therapeutics Inc

MedBiome Inc

Merck & Co Inc

Meridigen Biotech Co Ltd

METiS Pharmaceuticals

Novartis AG

Novo Nordisk AS

Oisin Biotechnologies

OPKO Health Inc

Opsidio LLC

Orgenesis Inc

OrthoTrophix Inc

Pharmaxis Ltd

Pharmicell Co Ltd

Poxel SA

ProKidney LLC

Purespring Therapeutics Ltd

Reata Pharmaceuticals Inc

Redx Pharma Plc

Rege Nephro Co Ltd

Reliance Life Sciences Pvt Ltd

Renibus Therapeutics Inc

Resverlogix Corp

Sarfez Pharmaceuticals Inc

Scohia Pharma Inc

Senda Biosciences Inc

Senolytic Therapeutics Inc

Sentien Biotechnologies Inc

Shenzhen Chipscreen Biosciences Co Ltd

TagCyx Biotechnologies

Unicocell Biomed Co Ltd

Unicycive Therapeutics Inc

Unicyte AG

Vascular BioSciences

VESSL Therapeutics Ltd

Vidasym Inc

Vivazome Therapeutics Pty Ltd

Vivoryon Therapeutics NV

Table of Contents

Table of Contents

Introduction

Chronic Kidney Disease (Chronic Renal Failure) - Overview

Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Development

Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment

Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development

Chronic Kidney Disease (Chronic Renal Failure) - Drug Profiles

Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects

Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products

Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Acacia Pharma Ltd, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Algernon Pharmaceuticals Inc, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Algomedix Inc, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Allena Pharmaceuticals Inc, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Angion Biomedica Corp, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Angiotensin Therapeutics Inc, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Annji Pharmaceutical Co Ltd, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Arch Biopartners Inc, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Aria Pharmaceuticals Inc, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Aronora Inc, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Ashvattha Therapeutics LLC, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by AstraZeneca Plc, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Bayer AG, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by BerGenBio ASA, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by BioAegis Therapeutics Inc, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by BioMarin Pharmaceutical Inc, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Boehringer Ingelheim International GmbH, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Boryung Pharmaceutical Co Ltd, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Cadila Healthcare Ltd, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Caladrius Biosciences Inc, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Cellmid Ltd, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Chinook Therapeutics Inc, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Chong Kun Dang Holdings Corp, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Cinkate Corp, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Daiichi Sankyo Co Ltd, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by DiaMedica Therapeutics Inc, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Dimerix Ltd, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Dizal (Jiangsu) Pharmaceutical Co Ltd, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by DJS Antibodies Ltd, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by DURECT Corp, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Evotec SE, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Future Medicine Co Ltd, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by G3 Pharmaceuticals Inc, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by GNI Group Ltd, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Goldilocks Therapeutics Inc, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Gubra ApS, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Helixmith Co Ltd, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Icagen Inc, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Immunitor Inc, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Indalo Therapeutics Inc (Inactive), 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by INVENT Pharmaceuticals Inc, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Ionis Pharmaceuticals Inc, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by KBP Biosciences Holdings Ltd, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Dormant Projects, 2021

Chronic Kidney Disease (Chronic Renal Failure) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports